Lantern Pharma Inc.
LTRN · United States
Share price · LTRN
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when LTRN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 10 Nov 2026-22.7%
- 28 Oct 2026+20.9%
Nothing announced by LTRN that day or the session before.
- 2 Oct 2026-14.0%
- 28 Sep 2026-10.7%
Nothing announced by LTRN that day or the session before.
- 24 Sep 2026-12.9%
- 22 Sep 2026-9.3%
Nothing announced by LTRN that day or the session before.
- 17 Sep 2026-11.4%
Nothing announced by LTRN that day or the session before.
- 16 Sep 2026+13.5%
Nothing announced by LTRN that day or the session before.
- 14 May 2026+24.7%
- 13 May 2026+21.8%
Nothing announced by LTRN that day or the session before.
Share of unusual movement by asset
For each asset, the share of LTRN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Dimesnaevents and moves
| 2 | shown from 8 days |
Zirdafulvenevents and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 4% |
| Other company news (earnings, financing, releases naming no asset) | — | 13% |
| Sessions with no dated event | — | 84% |
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | EGFR / ALK / MET / ROS1 (via extracellular disulfide-bond disruption) plus thioredoxin/glutaredoxin/peroxiredoxinSmall molecule | Non-Small Cell Lung Cancer | |
| Phase 1/2 | PTGR1 (Prostaglandin Reductase 1, bioactivating enzyme)Small molecule | Non-Small Cell Lung Cancer |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $1.8M | $6.7M+ $0.7M short-term inv. | $7.1M-$2.9M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | — | $1.7M | $4.9M+ $1.4M short-term inv. | $3.3M-$3.8M operating cash flow | report ↗ |
| 2025-Q3 | — | $2.4M | $8.4M+ $4.0M short-term inv. | $4.2M-$4.6M operating cash flow | report ↗ |
| 2025-Q2 | — | $3.1M | $6.1M+ $9.8M short-term inv. | $4.3M-$3.9M operating cash flow | report ↗ |
| 2025-Q1 | — | $3.3M | $6.4M+ $13M short-term inv. | $4.5M-$4.4M operating cash flow | report ↗ |
| 2024-Q3 | — | $3.7M | $8.1M+ $20M short-term inv. | $4.5M-$5.6M operating cash flow | report ↗ |
| 2024-Q2 | — | $3.9M | $13M+ $20M short-term inv. | $5.0M-$5.2M operating cash flow | report ↗ |
| 2024-Q1 | — | $4.3M | $18M+ $20M short-term inv. | $5.4M-$3.1M operating cash flow | report ↗ |
| 2023-Q3 | — | $2.2M | $26M+ $19M short-term inv. | $3.2M-$3.6M operating cash flow | report ↗ |
| 2023-Q2 | — | $3.6M | $28M+ $20M short-term inv. | $4.8M-$3.6M operating cash flow | report ↗ |
| 2023-Q1 | — | $2.5M | $32M+ $19M short-term inv. | $3.9M-$3.8M operating cash flow | report ↗ |
| 2022-Q3 | — | $0.7M | $39M+ $19M short-term inv. | $2.3M-$4.0M operating cash flow | report ↗ |
| 2022-Q2 | — | $3.0M | $43M+ $19M short-term inv. | $4.5M-$2.7M operating cash flow | report ↗ |
| 2022-Q1 | — | $2.7M | $47M+ $19M short-term inv. | $4.1M-$3.3M operating cash flow | report ↗ |
| 2021-Q3 | — | $3.0M | $55M+ $19M short-term inv. | $4.0M-$4.7M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $12M | $4.4M+ $5.7M short-term inv. | $4.3M-$16M operating cash flow | report ↗ |
Lantern Pharma did not disclose revenue for FY2025. R&D expense was $11.51M, down 28.6% YoY, and cash and equivalents were $4.42M at year-end, with a full-year net loss of $17.12M and quarterly net burn of $17.12M. Management also reported approximately $10.1M in cash, cash equivalents, and marketable securities.
Management guided that existing cash would fund operations until at least late July 2026 to mid-September 2026 and noted that substantial additional funding will be required. Clinical progress included continued LP-300 HARMONIC trial enrollment with an FDA Type C meeting scheduled for mid-May 2026, LP-184 Phase 1a completion with a 48% clinical benefit rate and planned biomarker-guided Phase 1b/2 trials, FDA IND clearance for Starlight Therapeutics’ STAR-001 pediatric CNS cancer trial, and LP-284 Orphan Drug Designation for soft tissue sarcomas. The company also advanced its RADR AI platform and introduced withZeta.ai, which entered beta testing with over 25 organizations.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $16M | $7.5M+ $17M short-term inv. | $5.2M-$18M operating cash flow | report ↗ |
| 2023-FY | — | $12M | $22M+ $19M short-term inv. | $4.0M-$14M operating cash flow | report ↗ |
| 2022-FY | — | $8.6M | $37M+ $18M short-term inv. | $3.6M-$13M operating cash flow | report ↗ |
| 2021-FY | — | $7.6M | $52M+ $19M short-term inv. | $3.1M-$11M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 2 purchases ($200K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-05-12 | KEYSER D JEFFREY · director | Open-market purchase | 48,544 | $2.06 | $100K | Form 4 |
| 2026-05-12 | Schalop Lee Troy · director | Open-market purchase | 48,544 | $2.06 | $100K | Form 4 |
| 2026-05-12 | KEYSER D JEFFREY · director | Open-market purchase (derivative) | 48,544 | $0.00 | $0 | Form 4 |
| 2026-05-12 | Schalop Lee Troy · director | Open-market purchase (derivative) | 48,544 | $0.00 | $0 | Form 4 |
| 2026-01-09 | Silberstein David S. · director | Award / grant (derivative) | 25,000 | — | — | Form 4 |
| 2026-01-09 | Schalop Lee Troy · director | Award / grant (derivative) | 25,000 | — | — | Form 4 |
| 2026-01-09 | Chandru Vijay · director | Award / grant (derivative) | 25,000 | — | — | Form 4 |
| 2026-01-09 | Maccecchini Maria-Luisa · director | Award / grant (derivative) | 25,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 32 reporting institutions held 2.1M shares ($2.8M, 14.5% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BIOS Capital Management, LP | 864,435 | $1.2M |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 332,079 | $455K |
| 3 | CM Management, LLC | 250,000 | $343K |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 116,000 | $159K |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 111,646 | $153K |
| 6 | Westside Investment Management, Inc. | 50,050 | $69K |
| 7 | Voss Capital, LP | 50,000 | $69K |
| 8 | VANGUARD FIDUCIARY TRUST CO | 49,607 | $68K |
| 9 | BlackRock, Inc. | 45,267 | $62K |
| 10 | DIMENSIONAL FUND ADVISORS LP | 38,060 | $52K |
| 11 | HORIZON KINETICS ASSET MANAGEMENT LLC | 26,373 | $36K |
| 12 | DAVENPORT & Co LLC | 23,814 | $33K |
| 13 | STATE STREET CORP | 23,652 | $32K |
| 14 | Bank of New York Mellon Corp | 21,301 | $29K |
| 15 | NORTHERN TRUST CORP | 15,589 | $21K |